Patient parameters and other radiation safety issues in 131I therapy for thyroid cancer treatment.
Patients administered with a therapeutic dose of I for thyroid cancer treatment are potential sources of unacceptably high radiation exposure to other individuals, particularly the patient's immediate family members. Generally, patients are hospitalized until such time that the retained radioactivity in the body or the measured dose rate at 1 m from the patient's body surface fall to within acceptable levels. Patient release criteria are set to ensure that no individual shall be liable to receive exposures above the regulatory dose limit for the public or dose constraints for the patient's relatives or caregivers.
Al-Haj
Abdalla N
AN
Biomedical Physics Department, King Faisal Specialist Hospital & Research Centre, MBC 03, PO Box 3354, Riyadh 11211, Saudi Arabia. abdal@kfshrc.edu.sa
Lagarde
Charlie S
CS
Lobriguito
Aida M
AM
D000293:Adolescent; D000328:Adult; D000368:Aged; D005260:Female; D006801:Humans; D007457:Iodine Radioisotopes / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011834:Radiation Monitoring; D011874:Radiometry; D019275:Radiopharmaceuticals / Q000009:adverse effects / Q000627:therapeutic use*; D013964:Thyroid Neoplasms / Q000532:radiotherapy*
D007457:Iodine Radioisotopes; D019275:Radiopharmaceuticals